-
A New Frontier in Treatment: FDA Approves Hovilpri (pritelivir) for Resistant HSV
A Breakthrough for Immunocompromised Patients For individuals living with immunocompromised conditions, managing mucocutaneous herpes simplex virus (HSV) can be a persistent and painful challenge. Recently, the medical community reached a significant milestone as the FDA approved Hovilpri (pritelivir), offering a new therapeutic option for those who struggle with lesions that do not respond to conventional…